2014至2016年我院门诊内科口服降糖药应用分析  

Analysis of application of oral hypoglycemic drugs in outpatient department of internal medicine in our hospital from 2014 to 2016

作　　者：林建昌[1] 汪铁山[1] 毕婷婷[1] 陈莉婧[1] 

机构地区：[1]广东省妇幼保健院药学部,广州511442

出　　处：《国际医药卫生导报》2017年第24期3924-3926,共3页International Medicine and Health Guidance News

摘　　要：目的了解2014至2016年本院门诊内科口服降糖药应用现状和发展趋势。方法采用回顾性分析法，对本院2014至2016年门诊内科口服降糖药的销售数量、销售总金额、用药频度（DDDs）、限定日费用（DDC）等数据进行统计和分析。结果2014至2016年本院门诊内科口服降糖药销售金额整体呈上升趋势，销售金额排名前3位的分别是瑞格列奈片、二甲双胍肠溶片和阿卡波糖片，其中二甲双胍肠溶片的DDDs连续3年稳居第1位；DDC排名较高的是瑞格列奈片和阿卡波糖片，较低的是格列齐特片和格列吡嗪片。结论本院2014至2016年门诊内科口服降糖药的使用基本合理。Objective To analyze the application status and development tendency of oral hypoglycemic drugs for outpatients in internal medicine of our hospital from 2014 to 2016. Methods By retrospective analysis, the utilization of oral hypoglycemic drugs for outpatients in internal medicine of our hospital from 2014 to 2016 was collected and analyzed statistically in respect of consumption amount, consumption sum, defined daily dose system （DDDs）, and daily drug cost （DDC）. Results The consumption sum of oral hypoglycemic drugs for outpatients in internal medicine of our hospital showed an increase tendency overall. Repaglinide, metformin, and acarbose ranked the first three places in consumption sum. The use frequency of metformin continuously dominated the first place during the last three years. Repaglinide and acarbose had higher DDC, while gliclazide and glipizide had lower DDC. Conclusion The application of oral hypoglycemic drugs for outpatients in internal medicine of our hospital is basically rational from 2014 to 2016.

关 键 词：口服降糖药 销售金额 用药频度 限定日费用 

分 类 号：R95[医药卫生—药学]